Business
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic corporate update. Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board, commented, “Following recent changes in executive management, the Company has conducted a review of its development programs, operating r
About this update from Indaptus Therapeutics, Inc.
[{"type":"image","alt":"Indaptus Therapeutics","displaySize":"","headline":null,"caption":"Indaptus Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":226,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/9c09e008af85eb0969fb44cb8570a245"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/padfAaQCWbS6HlU7crVYFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMg--/https://media.zenfs.com/en/globenewswire.com/9c09e008af85eb0969fb44cb8570a245","width":226,"height":60},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/padfAaQCWbS6HlU7crVYFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMg--/https://media.zenfs.com/en/globenewswire.com/9c09e008af85eb0969fb44cb8570a245","width":226,"height":60}},"lazy":false},{"type":"text","content":"NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic corporate update.","length":277,"tagName":"p"},{"type":"text","content":"Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board, commented, “Following recent changes in executive management, the Company has conducted a review of its development programs, operating resources and ongoing corporate initiatives. While this transition period involves certain operational and organizational adjustments, the Company remains focused on supporting and advancing its therapeutic and research activities.”","length":453,"tagName":"p"},{"type":"text","content":"“Currently we are evaluating our Decoy platform, including its preclinical data and underlying scientific rationale, as we assess its potential relevance to the Company’s ongoing therapeutic, immunological and translational research activities. As part of this process, we believe it is prudent to reassess the Company’s development priorities, operating initiatives and resource allocation considerations,” Mr. Dai commented.","length":426,"tagName":"p"},{"type":"text","content":"Key Highlights","length":14,"tagName":"p"},{"type":"text","content":"● Executive management transition. Recent changes in executive management have resulted in a transition period during which certain operational and organizational adjustments are underway. The Company continues to evaluate operat...